Related Experiment Video
Updated: Mar 24, 2026

Bilateral Renal Ischemia-Reperfusion Model for Acute Kidney Injury in Mice
Published on: February 2, 2024
Acute Kidney Injury Associated with Linagliptin
Deepak K Nandikanti1, Elvira O Gosmanova2, Aidar R Gosmanov3
1Kidney Specialists of Southern Nevada, Las Vegas, NV 89106, USA.
Abstract:
Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first case of linagliptin-associated acute kidney injury (AKI) in a patient with preexisting chronic kidney disease (CKD). We hypothesize that AKI was due to renal hypoperfusion from linagliptin-induced natriuresis and intravascular volume contraction in the setting of concomitant lisinopril use, which is known to impair autoregulation and potentiate hypotension-induced AKI. It may be prudent to exert caution and closely monitor kidney function when initiating linagliptin in combination with ACE-inhibitors in CKD patients.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury V: Interprofessional Care

